Show simple item record

dc.contributor.authorGonzález Martínez, Alicia
dc.contributor.authorGuerrero Peral, Angel Luis 
dc.contributor.authorArias Rivas, Susana
dc.contributor.authorSilva, Lorenzo
dc.contributor.authorSierra, Álvaro
dc.contributor.authorGago Veiga, Ana Beatriz
dc.contributor.authorGarcía Azorín, David
dc.date.accessioned2022-08-17T08:30:34Z
dc.date.available2022-08-17T08:30:34Z
dc.date.issued2022
dc.identifier.citationJournal of Neurology, 2022.es
dc.identifier.issn0340-5354es
dc.identifier.urihttps://uvadoc.uva.es/handle/10324/54400
dc.descriptionProducción Científicaes
dc.description.abstractBackground Headache is one of the most frequently reported symptoms in post-COVID patients. The clinical phenotype of COVID-19 headache combines phenotypic features of both tension-type headache (TTH) and migraine. We aimed to assess the efectiveness, side efects and predictors of amitriptyline (AMT) response in a real-world study setting. Methods We performed an observational multicentric study with a retrospective cohort. All consecutive patients with con frmed COVID-19 infection who received AMT for post-COVID headache from March 2020 to May 2021 were included. Response was evaluated by the reduction in the number of headache days per month (HDM) between weeks 8 and 12, compared with the baseline. We explored which variables were associated with a higher probability of response to AMT. Results Forty-eight patients were eligible for the study, 40/48 (83.3%) females, aged 46.85 (SD: 13.59) years. Patients had history of migraine 15/48 (31.3%) or TTH 5/48 (10.4%). The mean reduction of HDM was 9.6 (SD: 10.9; 95% CI 6.5, 12.7) days. Only 2/48 (5%) of patients discontinued AMT due to poor tolerability. History of TTH (10.9, 95% CI 1.3, 20.6) and nausea (−8.5, 95% CI −14.6, −2.5) were associated with AMT response. Conclusions This study provides real-world evidence of the potential beneft of AMT in patients with post-COVID-19 headache, especially in patients with history of TTH and without concomitant nausea.es
dc.format.mimetypeapplication/pdfes
dc.language.isoenges
dc.publisherSpringeres
dc.rights.accessRightsinfo:eu-repo/semantics/openAccesses
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subject.classificationMigrainees
dc.subject.classificationAmitriptylinees
dc.subject.classificationCOVID-19es
dc.subject.classificationTension-type headachees
dc.subject.classificationLong-haulerses
dc.titleAmitriptyline for post-COVID headache: effectiveness, tolerability, and response predictorses
dc.typeinfo:eu-repo/semantics/articlees
dc.rights.holder© 2022 The Authorses
dc.identifier.doi10.1007/s00415-022-11225-5es
dc.relation.publisherversionhttps://link.springer.com/article/10.1007/s00415-022-11225-5es
dc.identifier.publicationtitleJournal of Neurologyes
dc.peerreviewedSIes
dc.description.projectMinisterio de Economía y Competitividad (Instituto de Salud Carlos III) & Unión Europea (Fondo Social Europeo, FSE+) a través del Río Hortega Beca (CM21/00178)es
dc.description.projectPublicación en abierto financiada por el Consorcio de Bibliotecas Universitarias de Castilla y León (BUCLE), con cargo al Programa Operativo 2014ES16RFOP009 FEDER 2014-2020 DE CASTILLA Y LEÓN, Actuación:20007-CL - Apoyo Consorcio BUCLEes
dc.identifier.essn1432-1459es
dc.rightsAtribución 4.0 Internacional*
dc.type.hasVersioninfo:eu-repo/semantics/publishedVersiones
dc.subject.unesco32 Ciencias Médicases


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record